CRSP CRISPR Therapeutics AG

8-K Current Report

Filed: March 11, 2026

Health Care

Biological Products, (No Diagnostic Substances)

CRISPR Therapeutics AG (CRSP) 8-K current report filed with SEC EDGAR on March 11, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Priced $550M convertible senior notes due 2031, upsized from initial $350M offering — 57% increase signals strong institutional demand
• Private placement via Rule 144A, sold only to qualified institutional buyers — no SEC registration, limits retail participation

+2 more insights

Other CRISPR Therapeutics AG 8-K Filings

8-K Mar 16, 2026

Get deeper insights on CRISPR Therapeutics AG

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.